RNS : FOR IMMEDIATE RELEASE |
8 JUNE 2016 |
ImmuPharma PLC
("ImmuPharma" or the "Company")
IMMUPHARMA HOSTS LUPUZOR ™ SYMPOSIUM
with
Lupuzor™s Inventor, Prof. Sylviane Muller
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to confirm that today and tomorrow, 8 & 9 June, it is hosting a number of presentations on Lupuzor™, the Company's lead compound for the potential treatment of Lupus, a chronic auto-immune disease, currently in a pivotal Phase III trial.
This event, to be attended by investors, sell side analysts and media, is being hosted with Prof. Muller, inventor of Lupuzor™ presenting on the unique 'Mechanism of Action' of Lupuzor™, also known by its chemical name 'Forigerimod' or 'P140'. Prof. Muller will also provide further evidence of the role the P140 molecule can take in the potential treatment of other autoimmune diseases.
Prof. Sylviane Muller was recently honoured by receiving 'The CNRS Medal of Innovation' for her discoveries made on the mechanism of action of Lupuzor™ and its applications to other autoimmune diseases.
A video of the presentation will be available to view on the Company's website from Monday 13 June on: www.immupharma.org/events&conferences.org.
No material new information relating to ImmuPharma will be disclosed during this event.
-Ends-
For further information please contact:
ImmuPharma plc (www.immupharma.org) |
+ 44 (0) 20 7152 4080 |
Tim McCarthy, Chairman |
|
Lisa Baderoon, Head of Investor Relations Twitter: @immupharma |
+ 44 (0) 7721 413496 |
Panmure, Gordon & Co., NOMAD & Broker |
+44 (0) 20 7886 2500 |
Fred Walsh, Duncan Monteith, Corporate Finance Charles Leigh-Pemberton, Corporate Broking |
|
|
|
Notes to Editors
ImmuPharma PLC
ImmuPharma is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need.
ImmuPharma announced on 1 March 2016 the successful completion of a £8.4 million fund raise, comprising a Placing and Subscription together with confirmation of EIS and VCT qualifying status. Monies raised will principally be used to complete the pivotal Phase III trial of Lupuzor™.
Lupuzor™
Lupuzor™ (also referred to as Forigerimod, or P140) is ImmuPharma's lead compound and a potential treatment for lupus (or Systemic Lupus Erythematosus), a chronic, potentially life-threatening auto-immune disease. Lupuzor™ has a novel mechanism of action aimed at modulating the body's immune system so that it does not attack healthy cells, and avoids causing adverse side effects. It has the potential to halt the progression of the disease in a substantial proportion of patients.
Lupuzor™ has been granted Fast Track status by the US FDA and approval to start Phase III under Special Protocol Assessment (SPA). This SPA was subsequently amended due to its strong safety and efficacy profile to allow for a reduced number of patients in the pivotal Phase III trial thereby reducing the projected cost and time of development considerably.
The pivotal Phase III clinical study is entitled "A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus". It is a pivotal study designed to demonstrate the safety and efficacy of IPP-201101 and as a last step prior to the filing of the drug for approval with the US Food & Drug Administration ("FDA") and the European Medicines Agency ("EMA"). For more information please visit: www.ClinicalTrials.gov/lupuzor
Commercial Opportunity
There are an estimated five million people globally suffering from Lupus, with approximately 1.5 million patients in the US, Europe and Japan (Source: Lupus Foundation of America). Current 'standard of care' treatments, including steroids and immunosuppressants, can potentially have either serious side effects for patients or limited effectiveness, with over 60% of patients not adequately treated. GSK's Benlysta is the first Lupus drug approved in over 50 years and paves the path to market for Lupuzor™. Based on conservative estimates, and taking into account that Benlysta is priced currently at approximately $35,000 per patient per year, Lupuzor™ would be entering a market with the potential for multi-billion dollar sales. For more information on Lupuzor™ please visit: www.lupuzor.com
